Quick Answer
Clinical trials in India are governed by the New Drugs and Clinical Trials Rules 2019, significantly amended in 2023, and administered by the Central Drugs Standard Control Organisation (CDSCO). Sponsors must obtain Institutional Ethics Committee approval, CDSCO permission for regulated trials, and register on the Clinical Trials Registry of India before enrolling the first participant. The 2023 amendments introduced mandatory audio-visual documentation for informed consent and strengthened formula-based compensation obligations for trial-related injuries.
India has established itself as one of the world’s most strategically significant clinical trial destinations, offering a large, genetically diverse patient population, a substantial network of qualified investigators, and a regulatory framework that has progressively aligned with international standards. The New Drugs and Clinical Trials Rules 2019 (NDCT Rules), issued under the Drugs and Cosmetics Act 1940, constitute the primary legal instrument governing clinical trials in India. Amendments introduced in 2023 materially revised requirements for informed consent documentation and sponsor compensation liability, introducing obligations that every clinical trial sponsor, contract research organization (CRO), and investigational site must now operationalize.
For clinical research professionals, regulatory affairs heads, and biotech companies conducting trials in India, understanding the current legal framework is not a preliminary concern. It is a prerequisite for lawful trial conduct. Non-compliance with the NDCT Rules can result in clinical trial suspension, revocation of CDSCO permission, and significant legal and financial liability.
This guide provides a structured analysis of the legal requirements under the NDCT Rules 2019 (as amended in 2023), the step-by-step approval process, informed consent obligations, compensation frameworks, and intellectual property considerations in clinical trial agreements. Altacit Global advises sponsors, CROs, and investigational sites across India on the full compliance lifecycle for regulated clinical trials.
Why Is India a Major Clinical Trial Hub?
India’s prominence in global clinical research reflects several structural advantages that distinguish it from other trial destinations.
India’s patient population exceeds 1.4 billion, with a high prevalence of therapeutic areas of global clinical interest, including oncology, cardiovascular disease, diabetes, and infectious diseases. This enables sponsors to achieve statistically significant enrollment at substantially lower cost and within shorter timelines than many Western markets.
The availability of experienced principal investigators, accredited clinical research sites, and English-language regulatory documentation further reduces operational friction for international sponsors. India’s cost structure for trial conduct, including investigator fees, patient management, and laboratory analysis, remains considerably more competitive than the United States or European Union.
From a regulatory standpoint, CDSCO’s 30-working-day approval timeline for clinical trial permissions reflects a statutory commitment to efficiency. This timeline, established under the NDCT Rules, applies to applications for new drug clinical trials submitted through the SUGAM portal (sugam.pharma.gov.in).
India also participates in the International Council for Harmonisation (ICH) framework. Sponsors must conduct trials in conformity with ICH E6 Good Clinical Practice (GCP) guidelines, ensuring that data generated in India meets international regulatory standards for submissions to the United States Food and Drug Administration (USFDA), the European Medicines Agency (EMA), and other authorities.
What Is the Legal Framework Governing Clinical Trials in India?
The New Drugs and Clinical Trials Rules 2019 serve as the central regulatory instrument for clinical trials in India, replacing the earlier Schedule Y framework under the Drugs and Cosmetics Act 1940. The NDCT Rules govern the approval, conduct, safety monitoring, and data reporting requirements for clinical trials of new drugs, biologicals, and investigational medical devices.
The 2023 amendments to the NDCT Rules introduced two categories of substantive change. First, the amendments revised informed consent requirements, mandating audio-visual documentation of the consent process for vulnerable and illiterate participant populations. Second, the amendments strengthened sponsor liability for trial-related injury compensation, clarifying the formula-based calculation methodology and confirming that sponsor compensation obligations are non-waivable by contract.
CDSCO, operating under the Ministry of Health and Family Welfare, administers all clinical trial permissions in India. All applications, including submissions for new drug clinical trials and bioavailability and bioequivalence (BA/BE) studies, are processed electronically through the SUGAM portal.
The Clinical Trials Registry of India (CTRI), maintained by the Indian Council of Medical Research (ICMR), functions as the mandatory prospective registration platform. CTRI registration must be completed before the first participant is enrolled.
Sponsors and investigators are additionally bound by ICH E6 GCP guidelines, which CDSCO has adopted by reference under the NDCT Rules. Compliance with ICH E6 GCP is a condition of clinical trial permission, and CDSCO inspections assess adherence to these standards.
Step-by-Step Clinical Trial Approval Process in India
Step 1: Institutional Ethics Committee (IEC) Approval
Institutional Ethics Committee approval is the first mandatory regulatory step for any clinical trial conducted in India. An IEC must be registered with CDSCO under the NDCT Rules. The IEC reviews the trial protocol, investigator qualifications, patient information sheets, informed consent documents, and compensation arrangements before granting approval.
IEC approval must be obtained before the clinical trial application is submitted to CDSCO for trials requiring regulatory permission. The IEC remains operationally active throughout the trial, reviewing protocol amendments, serious adverse event reports, and annual progress reports.
Step 2: CDSCO Permission (For Regulated Trials)
Clinical trials of new drugs, investigational biologicals, and certain medical devices require prior CDSCO permission under Rule 44 of the NDCT Rules. Applications are submitted through the SUGAM portal with the complete investigational new drug dossier, proposed protocol, IEC approval letter, and other prescribed documents.
CDSCO must act on the application within 30 working days from the date of receipt of a complete submission. If CDSCO does not communicate a decision within this statutory period, permission is deemed granted for certain categories of trials. However, sponsors should not rely on deemed approval without formal confirmation. BA/BE studies for generic drugs do not require CDSCO permission but do require IEC approval and CTRI registration.
Step 3: Registration on CTRI
All clinical trials conducted in India, whether interventional or observational, must be registered on the Clinical Trials Registry of India before the first participant is enrolled. CTRI registration is a mandatory requirement under the NDCT Rules and is also a prerequisite for publication in most peer-reviewed medical journals.
The registration submission must include the trial title, sponsor details, protocol summary, primary and secondary endpoints, eligibility criteria, and investigational site information. CTRI assigns a unique registration number that must be referenced in all subsequent regulatory submissions and publications.
Step 4: Participant Enrolment and Informed Consent
Informed consent must be obtained from each participant, or their legally authorized representative, before any trial-related procedure is initiated. The informed consent process must comply with the requirements set out in Schedule Y of the NDCT Rules and the 2023 amendment provisions on documentation.
The consent document must be provided in the participant’s local language. For illiterate participants and members of vulnerable populations, the 2023 amendments require audio-visual documentation of the entire consent process. This documentation must be retained at the investigational site and made available to CDSCO inspectors and IEC reviewers upon request.
Step 5: Trial Conduct and Safety Monitoring
All trial conduct must conform to the approved protocol, ICH E6 GCP guidelines, and CDSCO’s applicable directives. Investigators must report serious adverse events (SAEs) to the sponsor, the IEC, and CDSCO within the timelines prescribed under the NDCT Rules.
Sponsors are required to establish a Data Safety Monitoring Board (DSMB) for Phase II, Phase III, and Phase IV trials. The DSMB monitors accumulating safety and efficacy data and makes recommendations on trial continuation, modification, or termination.
Sponsor companies must submit periodic safety update reports (PSURs) to CDSCO for new drugs under clinical investigation, in accordance with CDSCO’s PSUR guidelines.
Step 6: Trial Completion and Data Submission
Upon trial completion, the sponsor must submit a final clinical study report to CDSCO in the prescribed format. For new drug applications intended for marketing approval in India, clinical data submitted must comply with Common Technical Document (CTD) formatting requirements.
The sponsor must also update the CTRI registration with trial completion status and key results. Trial master files must be archived for the minimum retention period specified under the NDCT Rules, which varies by trial phase and product development stage.
What Are the Informed Consent Requirements Under the 2023 NDCT Amendments?
The 2023 amendments to the New Drugs and Clinical Trials Rules materially expanded the legal obligations governing informed consent in India. These amendments apply to all regulated clinical trials conducted after the amendment notification date.
The core requirements under the current framework are as follows:
Requirement | Applicable Population | Documentation Standard |
Written informed consent in local language | All participants | Signed consent form retained at site |
Audio-visual (AV) documentation of consent process | Illiterate participants and vulnerable populations | Video recording archived at site |
Witness signature | Illiterate participants | Required alongside AV documentation |
Re-consent on protocol amendment | All participants affected by amendment | Updated consent form with new signature |
DSMB review before continuation | Phase II, III, IV trials | DSMB recommendation on file |
Audio-visual documentation must capture the full informed consent discussion, including the investigator’s explanation of risks, benefits, alternatives, and the participant’s voluntary agreement. Sponsors must include AV documentation procedures in the site’s standard operating procedures (SOPs) and verify compliance during monitoring visits.
Altacit Global advises clients that deficiencies in informed consent documentation constitute one of the most frequently cited findings in CDSCO inspections and IEC audits. Sponsors should implement protocol-level controls for AV documentation, rather than relying solely on site-level implementation.
How Does India's Compensation Framework Work for Trial-Related Injuries?
India operates a mandatory, formula-based compensation framework for participants who suffer trial-related injuries or death. This framework is established under the NDCT Rules and is non-waivable. Sponsors cannot contractually exclude or limit compensation liability below the formula-determined amount.
CDSCO’s compensation formula calculates the amount payable based on factors including the participant’s age, income, nature of the injury, degree of disability, and the causality assessment linking the adverse event to the investigational product or trial procedure.
Key structural features of India’s compensation framework are as follows:
- Causality assessment: The principal investigator conducts the initial causality assessment. In the event of a dispute, the IEC and, where required, CDSCO’s Expert Committee review the assessment.
- Sponsor liability: Compensation liability rests with the sponsor. Insurance or indemnity arrangements between sponsors and CROs do not affect the sponsor’s direct legal obligation to the participant.
- Non-waivability: Consent documents may not contain provisions by which participants waive their right to compensation. Any such waiver is void under the NDCT Rules.
- Timeline for payment: Compensation must be paid within a prescribed period following CDSCO’s final determination of liability and quantum.
Phase I trials conducted in India, particularly first-in-human studies, carry a heightened compensation exposure for sponsors given the absence of prior human safety data. Sponsors must ensure that their clinical trial insurance policies provide coverage that meets or exceeds the formula-determined compensation amounts for all enrolled participants.
Altacit Global assists sponsors in structuring compensation clauses in clinical trial agreements and verifying that insurance arrangements satisfy CDSCO’s requirements before submission of the trial permission application.
What IP Considerations Apply to Clinical Trial Agreements in India?
Clinical trial agreements (CTAs) executed between sponsors and investigational sites in India must expressly address intellectual property ownership. Under Indian law, there is no automatic statutory vesting of IP rights arising from trial conduct in any single party. Ownership of data, inventions, and biological materials generated during the trial is determined entirely by the terms of the executed agreement.
The following IP provisions must be specified in every CTA:
- Ownership of trial data and study results: The CTA must identify which party owns the clinical data, case report forms, and trial results. Sponsors typically retain ownership of all trial data as a condition of regulatory submission rights.
- Background IP protection: Site-owned background IP, including existing research methodologies and pre-existing know-how, must be clearly delineated to prevent unintended transfer or licensing to the sponsor.
- Foreground IP and inventions: Inventions arising from trial conduct, including novel therapeutic uses, dosing regimens, or biomarker discoveries identified during the trial, must be assigned or licensed under clearly specified terms. Without an express assignment clause, a site investigator who makes an invention during the trial may claim ownership under the Patents Act 1970.
- Publication rights: CTAs must specify whether the investigational site has the right to publish trial results independently, the notice period required before publication, and the sponsor’s right to review publications for confidential information and patentable inventions.
- Biological material and sample rights: Where the trial involves collection of biological samples, the CTA must address ownership, storage, secondary use rights, and transfer restrictions in accordance with India’s Biological Diversity Act 2002 and applicable ICMR guidelines.
For sponsors conducting multinational trials with Indian sites, Altacit Global strongly recommends that CTA templates be reviewed and adapted to Indian law before execution. Standard international CTA templates frequently do not address Indian-specific legal requirements, including NDCT Rules compliance clauses and CTRI registration obligations.
For a comprehensive analysis of intellectual property protection strategies for healthcare and pharmaceutical companies operating in India, see Altacit Global’s resources on healthcare and pharma IP advisory.
Engage Altacit Global for Clinical Trial Regulatory Advisory in India
Compliance with the New Drugs and Clinical Trials Rules 2019, as amended in 2023, requires precise coordination across IEC approvals, CDSCO submissions, CTRI registration, informed consent documentation, compensation structuring, and clinical trial agreement drafting. Sponsors, CROs, and investigational sites that operate without expert regulatory and legal guidance face material compliance risk at every stage of the trial lifecycle.
Altacit Global provides comprehensive advisory services for clinical trial stakeholders in India, including:
- CDSCO clinical trial permission applications and regulatory strategy
- IEC registration and ethics committee liaison support
- CTRI registration and trial registry management
- Informed consent document drafting and audio-visual documentation protocols compliant with the 2023 amendments
- Trial-related injury compensation assessments and insurance coverage review
- Clinical trial agreement drafting, review, and negotiation, including IP, data ownership, and publication rights
- ICH E6 GCP compliance audits and inspection readiness programs
Altacit Global operates from offices in Hyderabad and Chennai, serving sponsor companies, CROs, academic medical centers, and biotech companies across India and internationally.
To discuss your clinical trial regulatory requirements in India, contact our team at info@altacit.com.
Frequently Asked Questions: Clinical Trials India
Q1: Can Phase I trials be conducted in India for drugs not tested abroad?
Yes, under the New Drugs and Clinical Trials Rules 2019, Phase I first-in-human trials can be conducted in India for drugs that have not yet been tested in any other country. Historically, India required Phase I data from at least one other jurisdiction before permitting Phase I trials domestically. The NDCT Rules 2019 removed this restriction, positioning India as a viable destination for early-phase global development programs. CDSCO permission is required, and the application must include a complete investigational new drug dossier with preclinical safety data, a Phase I protocol, and IEC approval.
Q2: What are the compensation rates for trial-related injury in India?
India does not publish a fixed compensation schedule. Instead, compensation is calculated using a formula prescribed by CDSCO that takes into account the participant’s age, annual income, the nature and severity of the injury or disability, and a causality factor reflecting the degree to which the injury is attributable to the investigational product or trial procedure. The formula was most recently revised to strengthen sponsor liability and remove ambiguity in causality-based adjustments. Sponsors should model potential compensation exposure based on the participant population before finalizing trial insurance coverage.
Q3: Is CTRI registration mandatory for all clinical trials in India?
Yes. Registration on the Clinical Trials Registry of India is mandatory for all clinical trials conducted in India, whether interventional or observational, under the New Drugs and Clinical Trials Rules 2019 and ICMR’s clinical trial registration policy. CTRI registration must be completed prospectively, before the first participant is enrolled. Retroactive registration is not permitted for trials initiated after the NDCT Rules came into force. Failure to register on CTRI before enrollment constitutes a violation of the NDCT Rules and may result in the trial data being rejected by CDSCO and peer-reviewed journals.
Q4: Who can serve as a Principal Investigator in an Indian clinical trial?
A Principal Investigator (PI) conducting a clinical trial in India must be a qualified medical professional registered under the applicable state medical council, possess relevant therapeutic area expertise, and have completed Good Clinical Practice training recognized by CDSCO. The PI must have access to adequate facilities, qualified study staff, and the infrastructure necessary to conduct the trial in accordance with the approved protocol and ICH E6 GCP guidelines. CDSCO reviews PI qualifications as part of the clinical trial application review process. Sponsors are responsible for selecting and training PIs who meet these requirements before submitting the trial permission application.
